Antibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB2255 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB2255, RRID:AB_1580693
- Product name
- SLC29A1 polyclonal antibody
- Antibody type
- Polyclonal
- Description
- Rabbit polyclonal antibody raised against synthetic peptide of SLC29A1.
- Storage
- Store at 4°C. For long term storage store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Characterization and functional analysis of the promoter for the human equilibrative nucleoside transporter gene, hENT1.
Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney.
Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter.
Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T
British journal of cancer 2014 Sep 23;111(7):1275-84
British journal of cancer 2014 Sep 23;111(7):1275-84
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T
Surgery 2013 Apr;153(4):565-75
Surgery 2013 Apr;153(4):565-75
Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sueda T
Annals of surgical oncology 2012 Jul;19 Suppl 3:S646-55
Annals of surgical oncology 2012 Jul;19 Suppl 3:S646-55
Characterization and functional analysis of the promoter for the human equilibrative nucleoside transporter gene, hENT1.
Abdulla P, Coe IR
Nucleosides, nucleotides & nucleic acids 2007;26(1):99-110
Nucleosides, nucleotides & nucleic acids 2007;26(1):99-110
Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney.
Damaraju VL, Elwi AN, Hunter C, Carpenter P, Santos C, Barron GM, Sun X, Baldwin SA, Young JD, Mackey JR, Sawyer MB, Cass CE
American journal of physiology. Renal physiology 2007 Jul;293(1):F200-11
American journal of physiology. Renal physiology 2007 Jul;293(1):F200-11
Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter.
Bone DB, Hammond JR
American journal of physiology. Heart and circulatory physiology 2007 Dec;293(6):H3325-32
American journal of physiology. Heart and circulatory physiology 2007 Dec;293(6):H3325-32
No comments: Submit comment
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Western blot analysis of ENT1 (SLC29A1) (arrow) using rabbit SLC29A1 polyclonal antibody (Cat # PAB2255). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the ENT1 (SLC29A1) gene (Lane 2) (Origene Technologies).